From: The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
100
150
200
300
400
600
Melanoma Nivo
1 year PFS
0.650
0.682
0.710
0.738
0.754
0.759
Melanoma Nivo+IPI
0.766
0.775
0.784
0.788
0.795
NSCLC Pembrolizumab
0.732
0.750
0.764
0.776
0.782
0.790